Published by Pinnacle Pulse, maker of a self-tracking app. We have no affiliate or sales relationship with any peptide seller. Editorial policy →

Tirzepatide: what the research shows, and what it doesn’t

By Pinnacle Pulse Editorial Team · Status as of 16 October 2026 · Next scheduled update: 14 January 2027

Short answer: Tirzepatide is a prescription medicine that works on two gut-hormone receptors, GIP and GLP-1. Large randomized trials have tested it in type 2 diabetes and obesity. They, and the meta-analyses built on them, record gastrointestinal side effects and a possible gallbladder signal. Unapproved tirzepatide sold online falls outside all of that evidence.

What tirzepatide is

Your gut releases two hormones after a meal that matter here: GIP (the long name is glucose-dependent insulinotropic polypeptide) and GLP-1. Tirzepatide is a synthetic peptide that switches on the receptors for both. Older drugs in the class only hit GLP-1, which is why you’ll see tirzepatide described as a “dual agonist”.

The EU granted its first marketing authorization on 15 September 2022. Prescription only, in the EU and in the US.

What has been studied

Lots. Mostly in trials designed and funded by the manufacturer, because that’s how a drug reaches the market. So we give independent pooled analyses a bit of extra attention below.

SURMOUNT-1

If someone mentions “the tirzepatide obesity trial”, they probably mean this one. NEJM published it in 2022. It took 2,539 adults with obesity (or overweight plus a weight-related health problem) and left out anyone with diabetes. They got tirzepatide or placebo for 72 weeks, starting with a slow 20-week climb in dose.

Weight change was the main outcome, and tirzepatide beat placebo. Side effects were mostly gastrointestinal, mostly mild or moderate, and bunched up in those first months of dose increases. Depending on the dose group, 4.3% to 7.1% of people on tirzepatide dropped out because of adverse events. On placebo, 2.6%. Eli Lilly paid for the study.

Pancreas and gallbladder

Every drug in this family gets asked the same two questions, and tirzepatide is no exception.

Researchers in Chengdu pooled nine randomized trials in 2023 (Frontiers in Endocrinology, 9,871 participants with type 2 diabetes or obesity). Pancreatitis: no statistically significant increase. Gallbladder and bile-duct disease, lumped together: more common with tirzepatide than with placebo or basal insulin. The authors wrote that doctors should pay attention to it.

Two years later a different team, publishing in the Annals of Saudi Medicine, pooled 13 trials but only in people with obesity and no diabetes. Gut side effects were about three times as frequent as on placebo, most of them mild. And here’s the twist: in their data, tirzepatide showed no significant gallbladder risk.

Two analyses, two sets of trials, two answers. Honest reading? The gallbladder question is still open.

What the research does not show

Nothing in these papers applies to tirzepatide bought outside a pharmacy. FDA has warned about products labeled "for research purposes" or "not for human consumption", about fake compounded products bearing the names of pharmacies that never made them, and about dosing errors. By 31 May 2026 it had more than 730 adverse-event reports linked to compounded tirzepatide.

Long-term safety is unknown. SURMOUNT-1 lasted 72 weeks; people may take the drug for many years.

On gallbladder risk, see above. Pancreatitis is rare enough that even pooled trial data could miss a small increase.

And the people in these trials were screened, watched closely and seen often. What happens to an individual outside that setting is a different question.

Tirzepatide is an authorized prescription medicine in the EU and the US. In May 2026 FDA proposed leaving it off the list of bulk substances that outsourcing facilities may compound from, and it is not on FDA’s shortage list. WADA doesn’t ban it but has put it in the 2027 Monitoring Program. Details on our page Tirzepatide legal status.

FAQ

How does tirzepatide differ from semaglutide?

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Both are prescription medicines tested in large randomized trials.

What side effects were reported in trials?

Gastrointestinal effects were the most common, mostly mild to moderate and concentrated in the dose-escalation period. A 2023 meta-analysis also found more gallbladder or biliary disease, though a 2025 analysis in people without diabetes did not.

Does tirzepatide raise the risk of pancreatitis?

A 2023 meta-analysis of nine randomized trials found no statistically significant increase. Pancreatitis is uncommon, so a small effect can’t be excluded on the current data.

Sources

  • Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-16. PMID 35658024
  • Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1214334. PMID 37908750 (see also erratum, PMID 38549766)
  • Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025;45:129-43. PMID 40189856
  • FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
  • FDA. Federal Register, 1 May 2026: bulk drug substances proposed not to be included on the 503B bulks list (semaglutide, tirzepatide, liraglutide). govinfo.gov
  • EMA. Union Register data: centrally authorised medicines containing tirzepatide (first authorisation 15 September 2022). ema.europa.eu
  • USADA. Athlete advisory: what’s new on the 2027 WADA Prohibited List? usada.org

Facts last checked: 16 October 2026.

About this article

Written by: the Pinnacle Pulse Editorial Team, the people who make the Pinnacle Pulse app. We work only from primary sources such as regulators, legal texts, trial registries and PubMed, and we remove claims we can’t check against one.

This article has not been reviewed by a physician. It is general information, not medical advice.

Spotted an error? Our editorial policy explains how to report it and how we correct mistakes.

Change log

  • 16 October 2026: First published.

From the makers of this site: Pinnacle Pulse is a neutral tracking app. We don’t sell or recommend any substance. About Pinnacle Pulse

This article is for general information only. It is not medical advice and does not recommend the use of any substance. Decisions about medicines belong with a qualified healthcare professional.